Sleep Disorder Clinical Trial
Official title:
Evning Exposure to Computer Screen Disrupts Sleep, Attention and Biological Rhythms
Light exposure is on the rise in recent years. In large part because of unintentional
illumination from screens that emit light directly into the eyes. Millions of computers,
tablets, televisions, and smart-phones are sold worldwide every month and the usage time of
these devices is increasing constantly. Today, people are exposed to ongoing light exposure
from these device screens, emitting short wave length (SWL) during day and night hours,
whether as active or passive users. In sum, artificial light at night (ALAN) seem to affect
human circadian rhythmicity (melatonin and thermoregulation) and sleep, with two major
factors. First, wavelength of light, with SWL being most detrimental to sleep and rhythms,
when compared to LWL (Brianard et al., 2001). Second, a dose-response relationship exists
between increasing light intensity and poorer sleep/circadian rhythms (Brianard et al.,
1988; West et al., 2011).
Based on existing knowledge, we hypothesize that when compared to long wavelength LWL
illumination, short wavelength SWL illumination from computer screen will have a more
damaging effect on melatonin (MLT) production and secretion, interfering body temperature
regulation and affecting sleep quality, efficiency and sleep architecture. In addition, we
hypothesized that intensity of the screen illumination will play another important factor on
these outcomes, we assume that high intensity compared to low intensity will have more
damaging effect on: melatonin, thermoregulation and sleep.
Methods:
Participants Participants were between the ages of 20 and 45 years, with BMI 18-25, regular
sleep habits in Pittsburgh Sleep Quality Index (PSQI) questionnaire index<5 (Buysse et al.,
1989, Shochat et al., 2007), and a normative sleep-wake cycle type (Horne-Ostberg
morningness-eveningness questionnaire (Horne & Ostberg, 1976, Lavie & Segal, 1990) measured
Sleep quality and continuity were measured for one week using actigraphy with compatible
decoding software (Respironics Model II, Philips, Inc). Only participants with 6-8 hours of
sleep, normative sleep patterns, and no sleep/wake schedule problems proceeded to the
experimental phase of the study stage. Participants were healthy with no history of medical,
neurological, sleep disorders (confirmed by polysomnography) or psychiatric conditions and
no medication intake (excluding contraceptives for female participants). Participants with
ocular damage, such as to their field of vision, color blindness, or impaired functioning of
the pupil in reaction to light were excluded, however use of eyeglasses or contact lenses to
correct vision was allowed. Participants signed informed consent prior to participation in
the study. The study was approved by the Helsinki Committee of Assuta Medical Center and
Maccabi Health Services.
Measurements
Three physiological measures were collected in the study:
Polysomnography: The sleep testing room was a standard test room at the Sleep Medicine
Research Center at Assuta Medical Center. Standard in-lab polysomnography was conducted
using the Somnoscreen-polysomnography (PSG) type sleeping test instrument (Somnomedics,
Germany). Sleep channels included: electroencephalography (EEG), electro-oculography (EOG),
leg and chin electromyography (EMG), nasal breathing, chest breathing, diaphragm breath,
snoring, electro-cardio-graphy (EKG), heart rate, blood oxygen saturation, and body
position. Sleep data processing was performed by skilled and trained sleep technicians in
accordance with of the Rechtschaffen and Kales criteria (1968). Sleep continuity parameters:
latency to stage 1 (SL1) and stage 2 (SL2), percent wake after sleep onset (%WASO), index of
awakenings, total sleep time (TST), time in bed (TIB), and sleep efficiency (SE). Sleep
architecture parameters: percent stage 1 (%S1), stage 2 (%S2), REM (%REM), and SWS (%SWS),
index of sleep stage changes and REM onset latency (ROL).
Melatonin: Urine samples were collected for analyzing melatonin levels by measuring
6-sulfahydroxymelatonin (6-SMT) concentration, the major metabolite of the hormone in urine
(de Almeida et al., 2011). The quantitative determination of 6-SMT in urine was completed by
a solid phase enzyme-linked immunosorbent assay (ELISA # RE54031; IBL, Hamburg; Germany) as
described previously (Zubidat & Haim, 2007). 6-SMT concentrations (ng/mL) were
spectrophotometrically determined by ELISA microplate reader at 450 nm with reference
wavelength 650 nm (PowerWave HT, Biotek, Winooski; USA) and analyzed by Gen5TM Data Analysis
Software (Version 2, Biotek, Winooski; USA).
Urine samples were collected on all four days of the experiment at three time points: 21:00,
23:00 and at wake time. All urine samples were frozen (-20OC) immediately after collection.
Melatonin was then analyses and secretion parameters were estimated. As the first morning
sample concentration of 6-SMT has been extensively used as an estimate of overnight
melatonin secretion (McMullan et al., 2013), we used this sample to represent the maximum
(100%) MLT secretion per participant. The night samples (at 21:00 and 23:00) were
transformed using the formula value at 21:00 or 23:00 /value in wake time *100 to reflect
the percentage change in MLT secretion per participant.
Temperature: Oral temperature was measured using an electronic oral thermometer (Domotherem,
UEBE Medical GMBH, Germany).
Procedure:
Recruitment ads were placed in social network websites stating basic inclusion criteria and
study details. Interested persons were initially interviewed via phone to rule out major
exclusion criteria (e.g. age, general health, and sleep patterns). Persons who were eligible
and interested in participating were invited to the sleep laboratory at Assuta Medical
Center (Tel Aviva, Israel) for in-lab screening. At the screening visit, all participants
signed informed of consent and filled out intake questionnaires, including demographic and
health questionnaires, PSQI, and the Horne-Ostberg questionnaire). Participants then
received an actigraph for one week to assess the quality and quantity of their sleep and
sleep wake patterns and schedules.
Following the home screening, participants were scheduled for four in-lab testing nights
across two consecutive weeks. Participants were always scheduled on Sunday and Wednesday
nights for each week. For the duration of the 2-week experimental period, all participants
were requested to sleep in accordance with their normal sleep schedule, both at home and at
the laboratory.
A repeated measures design was used, with two independent variables: screen luminance (or
light intensity emitted from the screen) and light wavelength. The first, luminance at two
levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2). The second, wavelength at
two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k). Luminance and
wavelength levels were measured and adjusted using a light metering device
(AvaSpec-2048-FT-SDU; Avantes, Inc., Eerbeek, Netherlands). There were three dependent
measures that were analyzed separately, sleep, melatonin secretion, and oral temperature.
Each participant underwent all four experimental conditions in counterbalanced order.
Participants arrived at sleep laboratory at 21:00h on all experimental nights. The
experiment room was about 12 m2 in size and included a desk with a 22-inch computer LED
(Light Emitting Diode) screen (Model 226V4L, Philips, USA) and a bed. The screen was placed
at a distance of about 60 cm from the participant and at eye level.
The room was dark and the room temperature was set to 22OC. Participants sat in front of the
computer screen for two hours and performed onscreen tasks between 21:00h and 23:00h. Tasks
were reading texts and answering related questions, writing exercises and solving verbal and
arithmetic problems. Participants were not informed of the differing light conditions and
were told that the purpose of the study is to examine the effect of the content of the tasks
on sleep.
During exposure, the subjects were allowed to eat light food and drink (non-caffeinated
beverages only). Participants were requested to go to the bathroom before testing and were
not allowed leave the room for the duration of the testing. Following the light exposure,
participants were connected to the sleep testing system by a skilled technician and
requested to go to sleep. Bedtimes and wake times were based on the average sleep/wake time
as indicated in the individual actigraphy reports. Oral temperature was taken at six time
points, three on the testing night: 21:00h, 23:00h, and immediately prior to bedtime and at
three the following morning, at 0, 60, and 120 minutes after awakening. Urine samples were
collected at three time points: 21:00h, 23:00h, and immediately following morning awakening.
This protocol was repeated for each of the four testing nights. Upon completion of the study
protocol participants were given monetary compensation for their participation in the study.
Statistical analysis:
Two-way (wavelength X intensity) repeated measures (RM) ANOVAs were performed to evaluate
mean value differences for all sleep parameters. Three-way (wavelength x intensity X time)
RM ANOVAs were performed to evaluate mean value differences in melatonin and temperature
indices. Post-hoc Tukey tests were performed for significant ANOVAs. Two-tailed p-values
below 0.05 were considered significant. Statistical analyses were preformed using SPSS,
version 20 (SPSS Inc., Chicago, IL, USA).
;
Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Recruiting |
NCT04786314 -
The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome
|
N/A | |
Recruiting |
NCT05775731 -
Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
|
||
Recruiting |
NCT03326765 -
Characterizing Sleep Disorders in Children and Adults With Tuberous Sclerosis Complex (TSC)
|
N/A | |
Completed |
NCT03673397 -
The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression
|
N/A | |
Completed |
NCT03903263 -
Sleep Disturbances in Dermatology Patients
|
||
Not yet recruiting |
NCT05950932 -
Effects of Melissa Extract on Sleep Characteristics
|
Phase 4 | |
Not yet recruiting |
NCT06012513 -
Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis
|
||
Completed |
NCT01463839 -
Sleep Disorder and Oral Habits in Children
|
N/A | |
Completed |
NCT00940589 -
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
|
Phase 2 | |
Recruiting |
NCT06093633 -
A Prospective Study to Evaluate the WP in Comparison to PSG in Patients Suspected of Sleep Disorders
|
||
Completed |
NCT06108115 -
Smartphone-Based Intervention for Sleep Disturbance in Individuals Recovering From Alcohol Use Disorder
|
N/A | |
Completed |
NCT05511818 -
Radicle Rest: A Study of Cannabinoids on Sleep and Health Outcomes
|
N/A | |
Active, not recruiting |
NCT04291014 -
Light Therapy for PD - Dose Selection
|
N/A | |
Completed |
NCT04560595 -
Remote Guided Caffeine Reduction
|
N/A | |
Completed |
NCT06008470 -
Investigation of Respiratory Muscle Strength, Exercise Capacity, Physical Activity and Sleep Quality Level in Individuals With Covid-19 Infection
|
||
Recruiting |
NCT06129942 -
Light Therapy in Parkinson's Disease
|
N/A | |
Recruiting |
NCT04318067 -
Melatonin in ADHD and Sleep Problems
|
Phase 4 | |
Completed |
NCT03532269 -
Validation of the Sleep Assessment Algorithm in the Medical Application Nightly
|
N/A | |
Completed |
NCT03857802 -
Efficiency of a Nursing Intervention in Sleep Hygiene
|
N/A |